Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02335229
Other study ID # 20-SMI-2013
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date June 2013
Est. completion date February 2017

Study information

Verified date January 2019
Source Abbott Medical Devices
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

20-SMI-2013 is a post market, observational, questionnaire based study to assess the effectiveness of the commercially available Axium neurostimulator in the management of chronic post surgical pain


Recruitment information / eligibility

Status Terminated
Enrollment 30
Est. completion date February 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subject is at least 18 years old

2. Subject is able and willing to comply with the follow-up schedule and protocol

3. Chronic post surgical pain for at least 6 months

4. Failed conservative treatments for chronic pain including but not limited to pharmacological therapy, physical therapy and interventional pain procedures for chronic pain

5. Minimum baseline pain rating of 60 mm on the Visual Analog Scale in the primary region of pain

6. Subject is able to provide written informed consent

7. Pain medication dosage has been stable for at least 30 days

8. Patient has been included for implantation according to standard criteria from the Dutch Neuromodulation Society

Exclusion Criteria:

1. Female subject of childbearing potential is pregnant/nursing, plans to become pregnant or is unwilling to use approved birth control

2. Escalating or changing pain condition within the past month as evidenced by investigator examination

3. Subject has had corticosteroid therapy at an intended site of stimulation within the past 30 days

4. Subject has had radiofrequency treatment of an intended target Dorsal Root Ganglion within the past 3 months

5. Subject currently has an active implantable device including implantable cardioverter defibrillator, pacemaker, spinal cord stimulator or intrathecal drug pump

6. Subject is unable to operate the device

7. Subjects with indwelling devices that may pose an increased risk of infection

8. Subjects currently has an active infection

9. Subject has participated in another clinical investigation within 30 days

10. Subject has a coagulation disorder or uses anticoagulants that, in the opinion of the investigator, precludes participation

11. Subject has been diagnosed with cancer in the past 2 years.

12. Patient has no other exclusion criteria according to standard criteria from the Dutch Neuromodulation Society

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Axium DRG Neurostimulator
Implantation with Axium DRG Neurostimulator

Locations

Country Name City State
Netherlands Academisch Medisch Centrum Amsterdam

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Pain Intensity for Overall Pain From Pre-treatment Baseline The Visual Analog Scale (VAS) is self-administered instrument assessing average pain intensity. Subjects rated their pain on a horizontal line, 10 cm in length, anchored by word descriptors on each end (no pain to worst imaginable pain). A higher score indicates a higher pain level. The values range from 0 (minimum pain) to 10 (maximum pain). Baseline, 3, 6, 12 and 24-Month Visits
Primary Percentage of Subjects With at Least 50% Pain Reduction Percent of subjects with at least a 50% reduction. The Visual Analog Scale (VAS) is self-administered instrument assessing average pain intensity. Subjects rated their pain on a horizontal line, 10 cm in length, anchored by word descriptors on each end (no pain to worst imaginable pain). A higher score indicates a higher pain level. The values range from 0 (minimum) to 10 (maximum). 3, 6, 12 and 24-Month Visits
See also
  Status Clinical Trial Phase
Recruiting NCT05787691 - Enhanced vs.Standard Pain Management of Patients at Risk for Chronic Post-surgical Pain N/A
Recruiting NCT05764681 - Chronic Postsurgical Pain
Completed NCT04876989 - The Comparison of Sympathetic Blockade of Stellate Ganglion Block and Thoracic Paravertebral Block N/A
Recruiting NCT05739747 - Validation of the Gendolcat Score for the Prognosis of Chronic Postoperative Pain in Cesarean Section